Phase III study: Immunotherapy + chemo combination for advanced lung cancer prolongs life, improves QOL

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A recent clinical trial demonstrated that the drug combination of cemiplimab plus platinum chemotherapy can prolong survival in patients with advanced lung cancer when compared with placebo plus platinum chemotherapy.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login